Healthcare / Pharmaceutical RetailersKOSDAQ
$2225.00
-40.00 (-1.77%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-14.8B · quality 56.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$75.3B
P/E
N/A
•EV/EBITDA
87.1x
↑ROE
-10.1%
↓Gross Margin
10.0%
↓Debt/Equity
0.92
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+34.1%
FCF CAGR
—
FCF margin
1.6%
FCF / Net income
-0.67x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $185.91B · net income $-4.51B · FCF $3.04B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $185.91B | $185.91B | $133.29B | $113.85B | $77.15B |
| Net Income | $-4.51B | $-4.51B | $-4.80B | $-2.34B | $-14.24B |
| EBITDA | $1.21B | $1.21B | $-662.2M | $-1.47B | $-12.66B |
| EPS | -134.00 | -134.00 | -48.67 | -88.33 | -697.00 |
| Gross Margin | 10.0% | 10.0% | 10.0% | 12.5% | 16.9% |
| Operating Margin | -1.1% | -1.1% | -5.2% | 1.2% | 1.2% |
| Net Margin | -2.4% | -2.4% | -3.6% | -2.1% | -18.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.92 | 0.92 | 0.90 | 0.67 | 9.30 |
| Current Ratio | 0.66 | 0.66 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $3.04B | $3.04B | $-14.76B | $-21.87B | $-9.46B |
| Returns | |||||
| ROE | -10.1% | -10.1% | -10.2% | -5.2% | -1208.4% |
| Valuation | |||||
| EV/EBITDA | 87.07 | 87.07 | — | — | — |
| P/B | 1.68 | 1.68 | 2.85 | 4.95 | — |
| Growth & Yield | |||||
| Revenue Growth | 39.5% | 39.5% | 17.1% | 47.6% | — |
| EPS Growth | -175.3% | -175.3% | 44.9% | 87.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-65.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-48.67 → -134.00
Residual
-65.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.